Telix Pharmaceuticals is trading 7.65% up at A$16.19 after investors continued absorbing strong second-quarter results and an improved full-year outlook.
- Q2 revenue reached US$247 million, up 21% year over year.
- Management indicated 2026 revenue and other income should exceed US$1 billion.
- Trading volume was 2,630,762 shares, above recent activity, suggesting strong participation. No separate August 10 announcement was identified.